ADAR1 Capital Management »

Voyager Therapeutics shares owned by ADAR1 Capital Management

Quarter-by-quarter ownership of Voyager Therapeutics (VYGR) shares owned by ADAR1 Capital Management from 13F filings

Historical chart of ADAR1 Capital Management investment in Voyager Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Voyager Therapeutics held by ADAR1 Capital Management consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Voyager Therapeutics by ADAR1 Capital Management

Quarter filed Position value Share count Share price at filing
2023-12-31 $1.6M 186k 8.44

More positions owned by ADAR1 Capital Management

Alnylam Pharmaceuticals (ALNY)
Royalty Pharma Shs Class A (RPRX)
Keros Therapeutics (KROS)
Roivant Sciences SHS (ROIV)
Cytokinetics Com New (CYTK)
Arbutus Biopharma (ABUS)
Bridgebio Pharma (BBIO)
Merrimack Pharmaceuticals In Com New (MACK)
Cerevel Therapeutics Hldng I (CERE)
Mirati Therapeutics
Merck & Co (MRK)
Ascendis Pharma A/s Sponsored Adr (ASND)
Immunovant (IMVT)
Viking Therapeutics (VKTX)
Protagonist Therapeutics (PTGX)

View all positions for ADAR1 Capital Management

Top funds holding Voyager Therapeutics

EcoR1 Capital
Vanguard Group
T. Rowe Price Associates
Dimensional Fund Advisors
AQR Capital Management
Federated Investors
D. E. Shaw & Co
Jpmorgan Chase & Co
Ikarian Capital
Fiduciary Trust Company
Bank of New York Mellon
Kestra Advisory Services
ADAR1 Capital Management
Goldman Sachs Group
TD Asset Management

View all funds holding Voyager Therapeutics